Verition Fund Management
ATNM icon

Verition Fund Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Verition Fund Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-59,300
Closed -$464K – 2978
2024
Q1 		$464K Buy
+59,300
New +$381K ﹤0.01% 2038

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Verition Fund Management's ATNM Position: Q4 2024 in Review

Verition Fund Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2024, closing a stake of 166,957 shares — an estimated $314K sold.

Verition Fund Management first reported a position in ATNM in Q1 2023 and held it in 4 quarters. The position peaked at $1.54M in Q1 2024. 69 funds tracked by Wall St. Rank hold ATNM as of Q4 2024.

  • Verition Fund Management reported no remaining Actinium Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Verition Fund Management sold 166,957 Actinium Pharmaceuticals shares in Q4 2024, an estimated $314K.
  • Verition Fund Management first reported a position in Actinium Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Verition Fund Management's Actinium Pharmaceuticals position peaked at $1.54M in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2024.

Based on Verition Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.